Acadia Pharmaceuticals (ACAD) reported $1.1B in revenue for fiscal 2025, +11.9% year on year. That ranks #1731 by revenue among 2853 SEC filers and #159 in Healthcare. Net income was $391M, a net margin of 36.5%. Revenue has grown 56.3% a year on average since 2011 ($2.1M then). The fiscal 2025 balance sheet shows $1.6B in total assets and $178M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.1B | +11.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $685M | +35.1% | FY20232023-12-31 |
| Operating incomeOperatingIncomeLoss | $105M | −54.6% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $391M | +73.0% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $110M | −30.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.7M | +796.7% | FY20252025-12-31 |
| Total assetsAssets | $1.6B | +31.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.2B | +67.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $178M | −44.4% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $268M | $3.6M | Open → |
| Q2 20262026-06-30 | $308M | $31.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 4 of 161 companies compared | 36.5% | |
| Operating marginRank 86 of 160 companies compared | 9.8% | |
| R&D as share of revenueRank 14 of 102 companies compared | 30.7% | |
| Cash as share of revenueRank 62 of 160 companies compared | 16.6% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Acadia Pharmaceuticals Inc
- Ticker
- ACAD
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001070494
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| NovavaxNVAX | $1.1B | $440M |
| Prestige Consumer HealthcarePBH | $1.1B | $190M |
| EmbectaEMBC | $1.1B | $95.4M |
| Acadia PharmaceuticalsACAD | $1.1B | $391M |
| Legend BiotechLEGN | $1.0B | −$297M |
| Tandem Diabetes CareTNDM | $1.0B | −$205M |
| Guardant HealthGH | $982M | −$416M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Acadia Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/acadia-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Acadia Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/acadia-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-acadia-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Acadia Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/acadia-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-072519 · February 26, 2026
{{cite web |title=Acadia Pharmaceuticals — Key figures — 10-K (0001193125-26-072519) |url=https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.